Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-19 02:49Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and failures in manufacturing compliance [1][5]. Group 1: Legal Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Jasper Therapeutics - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The alleged failures increased the risk of confounding results in ongoing studies and the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects [5].